Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 7/20 | 0.42 |
| ▸ | CTSS | P25774 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624281 | 0.84 | CTSK (0.48) | CTSKL3MBTL1CTSLCTSSALDH1A1 | |
| SCHEMBL13624322 | 0.79 | CTSL (0.56) | CTSKL3MBTL1CTSLCTSSCTSB | |
| SCHEMBL4367383 | 0.74 | CTSK (0.51) | CTSKALDH1A1 | |
| SCHEMBL13624440 | 0.73 | CTSL (0.47) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13624325 | 0.73 | CTSK (0.49) | CTSKCTSLALDH1A1 | |
| SCHEMBL13624418 | 0.72 | CTSL (0.57) | CTSKL3MBTL1CTSLCTSSCTSB | |
| SCHEMBL4366149 | 0.72 | CTSL (0.53) | CTSKL3MBTL1CTSLCTSSALDH1A1 | |
| SCHEMBL13624300 | 0.72 | CTSL (0.51) | CTSKCTSLCTSSALDH1A1CTSB | |
| SCHEMBL13624447 | 0.72 | CTSL (0.47) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13624384 | 0.71 | CTSL (0.47) | CTSKL3MBTL1CTSLCTSSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | CTSK 15/4885L3MBTL1 3079/4885CTSL 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.